Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a, Open-Label Study to Assess the Safety, Tolerability, and Efficacy of JK07 in Participants With Heart Failure and Group 2 Combined Post-Capillary and Pre-Capillary Pulmonary Hypertension (RENEU-PH)

NCT07221513 is registered in ClinicalTrials.gov with Salubris Biotherapeutics Inc as lead sponsor.

NCT NCT07221513
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07221513 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a, Open-Label Study to Assess the Safety, Tolerability, and Efficacy of JK07 in Participants With Heart Failure and Group 2 Combined Post-Capillary and Pre-Capillary Pulmonary Hypertension (RENEU-PH)
Lead sponsor
Salubris Biotherapeutics Inc
Phase
Phase 2
Overall status
Withdrawn
Start date
December 15, 2025
Completion date
April 16, 2026
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

group 2 pulmonary hypertension, hfpef - heart failure with preserved ejection fraction, hfref - heart failure with reduced ejection fraction